Oncolytics Biotech is trading 5.77% up at $0.79, with no clear company-specific catalyst identified for September 14, 2026.
- The September 10 announcement reported positive preclinical results combining pelareorep with a pan-RAS inhibitor in colorectal cancer, but the stock subsequently declined through September 11.
- Broader markets are lower, so today’s gain does not clearly align with overall market direction.